Brokerages predict that ContraFect Corporation (NASDAQ:CFRX) will post earnings per share (EPS) of ($0.16) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ContraFect Corporation’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). ContraFect Corporation reported earnings per share of ($0.35) during the same quarter last year, which would suggest a positive year over year growth rate of 54.3%. The company is expected to report its next quarterly earnings report on Tuesday, August 8th.
According to Zacks, analysts expect that ContraFect Corporation will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.75) to ($0.66). For the next year, analysts anticipate that the firm will report earnings of ($0.76) per share, with EPS estimates ranging from ($0.87) to ($0.63). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for ContraFect Corporation.
ContraFect Corporation (NASDAQ:CFRX) last issued its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02.
Separately, Maxim Group reaffirmed a “hold” rating on shares of ContraFect Corporation in a research report on Wednesday, March 15th.
A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP purchased a new position in shares of ContraFect Corporation (NASDAQ:CFRX) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned about 0.36% of ContraFect Corporation as of its most recent SEC filing. Hedge funds and other institutional investors own 44.64% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.